Table 6.

Hybrid nanoformulation

Diseases	Antiviral drug	Type of nanodelivery system	Lipid and polymer which used as carrier	Problems encountered	Key findings	Ref
HIV/AIDS	Zidovudine	Lipid–polymer hybrid nanoparticles	Stearic acid, Compritol 888 ATO, polymer Gelatin	Low aqueous solubility Short half-life and high side effects	High loading, hemocompatibility, sustained release	[232]
HIV/AIDS	Zidovudine	Lipid–polymer hybrid nanoparticles	Alginate, stearic acid, PEG	Biocompatibility problems, high toxicity	Biocompatibility, superior drug-loading capacity, and enhanced drug release efficacy	[233]
HIV/AIDS	Nevirapine	Lipid–polymer hybrid nanoparticles	PEG 400, propylene glycol, polyoxyethylene polyoxypropylene (copolymer), glyceryl monostearate, polyglyceryl distearate	Decreased solubility	Increased drug delivery to target sites	[233]
HIV/AIDS	Zidovudine	Core shell nanoparticle	Long-chain fatty acid, stearic acid, PEG, dextran	Biodegradability and biocompatibility	High stability, controlled drug release	[234]
HIV/AIDS	Zidovudine	Core shell nanoparticle	PVP, stearic acid, PEG	Short half-life Low bioavailability	Decreased systemic side effects, useful therapeutic activity	[235]